Biocon Limited (BIOCON) Price & Analysis

Compare

16 Followers

BIOCON Stock Chart & Stats

₹364.20

₹0.80(0.22%)

At close: Jan 09 4:00 PM EST

₹364.20

₹0.80(0.22%)

Day’s Range― - ―

52-Week Range₹290.80 - ₹424.95

Previous CloseN/A

Volume1.20M

Average Volume (3M)208.50K

Market Cap

₹613.40B

Enterprise Value₹641.62B

Total Cash (Recent Filing)₹60.89B

Total Debt (Recent Filing)₹164.33B

Price to Earnings (P/E)78.3

Beta1.30

Next Earnings

May 14, 2026

EPS Estimate

1.52

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)0.95

Shares Outstanding1,620,907,700

10 Day Avg. Volume177,351

30 Day Avg. Volume208,504

Financial Highlights & Ratios

PEG Ratio-38.08

Price to Book (P/B)1.88

Price to Sales (P/S)2.66

P/FCF Ratio23.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹421.00

Price Target Upside15.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained ~10.6% revenue growth indicates expanding product adoption and market reach across biosimilars, generics and CDMO services. Over 2-6 months this supports capacity utilization, funds R&D and commercial scale-up, and reduces reliance on one-time milestones for durable revenue.

Balance Sheet StrengthA healthy equity ratio and manageable leverage provide long-term financial flexibility to invest in biologics capacity and clinical programs. Robust capital structure lowers refinancing pressure, supports strategic partnerships, and cushions against sales or margin volatility over multiple quarters.

Cash Flow GenerationRising operating cash flow and positive free cash flow enable internal funding of capex, manufacturing expansion and R&D without heavy dilution. Strong cash conversion enhances resilience to cyclical pressures in pharma markets and underpins sustainable long-term investment in biosimilars and CDMO.

Bears Say

Increasing DebtAn increase in total debt raises interest and refinancing exposure and can constrain capital allocation for strategic projects. If revenue or margins slow, higher leverage could pressure cash flow and reduce flexibility to pursue long-term biologics programs or absorb regulatory setbacks.

EBIT Margin CompressionA falling EBIT margin signals rising operating costs or pricing pressure in core segments. Sustained margin compression would reduce internal funds for R&D and capacity, weaken profitability resilience against competition in biosimilars, and limit long-term reinvestment capability.

Earnings VolatilityA ~-67% EPS change points to earnings volatility that undermines predictability of cash available for growth. Persistent swings complicate budgeting for clinical and manufacturing investments, raise stakeholder uncertainty, and can hamper long-term partnership or licensing negotiations.

Biocon Limited News

Biocon Raises Rs 4,150 Crore via QIP to Fully Acquire Biocon Biologics

An update from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has raised Rs 4,150 crore...

1M ago

Biocon Raises ₹41.5 Billion via Qualified Institutions Placement, Expands Equity Base

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has raised approximately ₹41,500 million through a...

1M ago

Biocon Raises ₹41.5 Billion via QIP, Expands Equity Base

Biocon Limited ( ($IN:BIOCON) ) has provided an announcement. Biocon Limited has raised approximately ₹41,500 million through a...

1M ago

Biocon Closes QIP, Raises Capital Through Discounted Share Allocation

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has closed its Qualified Institutions Placement (QIP)...

1M ago

Biocon Clears Placement Document for Qualified Institutions Share Issue

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has approved and adopted a placement document...

1M ago

Biocon Subsidiary Wins USFDA Nod for Everolimus Oral Suspension Tablets

The latest update is out from Biocon Limited ( ($IN:BIOCON) ). Biocon Pharma Limited, a wholly owned subsidiary...

1M ago

Biocon Sets Record Date for Rs 200 Crore Listed Commercial Paper Maturity

An update from Biocon Limited ( ($IN:BIOCON) ) is now available. Biocon Limited has announced the record date...

2M ago

Biocon Lifts Stake in Biocon Biologics to 94% via Share Swap and Cash Deal

Biocon Limited ( ($IN:BIOCON) ) has issued an update. Biocon Limited has significantly increased its stake in its...

2M ago

Biocon Raises Stake in Biocon Biologics to 94% via Share Swap and Cash Deal

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited has increased its ownership in its unlisted...

2M ago

Biocon Shareholders Clear Capital Expansion, Preferential Issue and Higher Investment Limits at EGM

Biocon Limited ( ($IN:BIOCON) ) just unveiled an update. Biocon Limited reported the results of its Extraordinary General...

2M ago

BIOCON FAQ

What was Biocon Limited’s price range in the past 12 months?

Biocon Limited lowest stock price was ₹290.80 and its highest was ₹424.95 in the past 12 months.

What is Biocon Limited’s market cap?

Biocon Limited’s market cap is ₹613.40B.

When is Biocon Limited’s upcoming earnings report date?

Biocon Limited’s upcoming earnings report date is May 14, 2026 which is in 80 days.

How were Biocon Limited’s earnings last quarter?

Biocon Limited released its earnings results on Feb 12, 2026. The company reported ₹0.947 earnings per share for the quarter, missing the consensus estimate of ₹1.166 by -₹0.219.

Is Biocon Limited overvalued?

According to Wall Street analysts Biocon Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biocon Limited pay dividends?

Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here

What is Biocon Limited’s EPS estimate?

Biocon Limited’s EPS estimate is 1.52.

How many shares outstanding does Biocon Limited have?

Biocon Limited has 1,620,907,700 shares outstanding.

What happened to Biocon Limited’s price movement after its last earnings report?

Biocon Limited reported an EPS of ₹0.947 in its last earnings report, missing expectations of ₹1.166. Following the earnings report the stock price went down -0.146%.

Which hedge fund is a major shareholder of Biocon Limited?

Currently, no hedge funds are holding shares in IN:BIOCON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Biocon Limited

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

Biocon Limited (BIOCON) Earnings & Revenues

Historic Earnings Reports

BIOCON Stock 12 Month Forecast

Average Price Target

₹421.00

▲(15.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"301":"₹301","341":"₹341","381":"₹381","421":"₹421","461":"₹461"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":460,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹460.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":421,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹421.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹350.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[301,341,381,421,461],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,370.65,377.5230769230769,384.3961538461538,391.2692307692308,398.14230769230767,405.0153846153846,411.8884615384615,418.76153846153846,425.63461538461536,432.5076923076923,439.3807692307692,446.25384615384615,453.12692307692305,{"y":460,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,370.65,374.5230769230769,378.3961538461538,382.2692307692308,386.14230769230767,390.0153846153846,393.8884615384615,397.76153846153846,401.63461538461536,405.5076923076923,409.3807692307692,413.25384615384615,417.12692307692305,{"y":421,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,370.65,369.0615384615384,367.4730769230769,365.88461538461536,364.29615384615386,362.7076923076923,361.11923076923074,359.53076923076924,357.9423076923077,356.3538461538461,354.7653846153846,353.17692307692306,351.58846153846156,{"y":350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":362.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":333.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":361.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":382.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.5,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":372,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":394.5,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":387.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >